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a b s t r a c t
We generated a mouse model with a 162 nt AU-rich element (ARE) region deletion in the 30 untranslated
region (30UTR) of the interferon-gamma (IFN-g) gene that results in chronic circulating serum IFN-g
levels. Mice homozygous for the ARE deletion (ARE-Del) / present both serologic and cellular abnor-
malities typical of patients with systemic lupus erythematosus (SLE). ARE-Del/ mice display increased
numbers of pDCs in bone marrow and spleen. Addition of IFN-g to Flt3-ligand (Flt3L) treated in vitro bone
marrow cultures results in a 2-fold increase in pDCs with concurrent increases in IRF8 expression.
Marginal zone B (MZB) cells and marginal zone macrophages (MZMs) are absent in ARE-Del/ mice.
ARE-Delþ/ mice retain both MZB cells and MZMs and develop no or mild autoimmunity. However, low
dose clodronate treatment in ARE-Delþ/ mice specifically eliminates MZMs and promotes anti-DNA
antibody development and glomerulonephritis. Our findings demonstrate the consequences of a
chronic IFN-gmilieu on B220þ cell types and in particular the impact of MZB cell loss on MZM function in
autoimmunity. Furthermore, similarities between disease states in ARE-Del/ mice and SLE patients
suggest that IFN-gmay not only be a product of SLE but may be critical for disease onset and progression.
Published by Elsevier Ltd.
q The publisher or recipient acknowledges right of the U.S. Government to retain a nonexclusive, royalty-free license in and to any copyright covering the article.
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1. Introduction
The type II interferon, IFN-g, is well-recognized in murine lupus
models. IFN-g transgenic mice under the control of the involucrin
promoter develop a lupus-like syndrome defined by the autoanti-
body production, glomerular IgG deposition and glomerulone-
phritis [1]. Roquinsan/san mice display decreased IFN-g mRNA decay
leading to chronic circulating levels of IFN-g and a lupus-like
phenotype [2] and offspring from lupus-prone MRL/lpr mice
crossed with IFN-g/ mice have reduced autoantibody titers and
less severe end-organ disease [3]. In humans, IFNG gene poly-
morphisms have been identified in SLE cohorts [4,5] and dysregu-
lated NK cells, T cells, and PBMCs from SLE patients produce
elevated amounts of IFN-g that correlate with SLE Disease Activity
Index Scores [6e8]. Mechanistically, IFN-g induces B cell activating
factor (BAFF), a protein critical for B cell differentiation, prolifera-
tion, and survival that has been identified as a therapeutic target in
SLE [4,9].
Aberrant IFN-g expression is associated with inflammatory
diseases; thus, its expression is tightly controlled. Regulation is
complex and involves epigenetic modifications, IFNG promoter in-
teractions with positive and negative regulatory factors (reviewed
in [10]) and post-transcriptional control involving nuclear and
cytoplasmic mRNA compartmentalization, mRNA stabilization, and
miRNAs [11e13] that are partially mediated by IFN-g 30UTR in-
teractions with regulatory proteins human antigen R (HuR) and
tristetraprolin (TTP) [14,15]. Approximately 50% of the mature IFN-
g mRNA is 30UTR sequence. Little similarity between mouse and
human exist with the exception of a 162 nt AU-rich fragment
located in the 50 end of the 30UTR. AREs are best recognized as
mRNA destabilizing elements; thus, we predicted that removal of
the IFN-g ARE region would eliminate inhibitory functions result-
ing in chronic IFN-g mRNA and protein expression. Targeted dele-
tion of an ARE sequence was previously achieved for the tumor
necrosis factor-alpha (TNF-a) gene with subsequent elevated, sta-
ble TNF-a expression that coincided with inflammatory arthritis
and Crohn’s-like inflammatory bowel disease [16].
To examine the consequences of IFN-g ARE deletion on immune
function and potential disease development, we generated amouse
with a targeted substitution of the conserved 162 nt AU-rich
sequence with random nucleotides. The mice, henceforth called
ARE-Del mice, have low, chronic circulating IFN-g levels, a complex
phenotype consisting of neutrophilia, monocytosis, anti-nuclear
antibodies (ANAs), serum hypocomplementemia, glomerular
immunoglobulin and complement deposition, and mesangioproli-
ferative glomerulonephritis; findings consistent with disease
similar to human SLE. Importantly, heterozygote mice have normal
blood counts, lack elevated autoreactivity, and minimal renal le-
sions, indicating that a threshold level of IFN-g is critical for
development and exacerbation of disease.
2. Materials and methods
2.1. Generation of IFN-g ARE-Del mice
The IFN-g ARE targeting vector was obtained by recombineering
technology [17]. Briefly, we generated two 200 nt PCR fragments
from sequences flanking the 50 and 30 regions of the IFN-g 30UTR
ARE site. PCR products were cloned into PKB644:pLTM260 vector at
sites adjacent to a neomycin resistance gene cassette and flanked
by loxP and Frt sites. Replacement of the 162 nt ARE-rich sequence
was achieved by electroporation of the IFN-g/neomycin cassette
into DY380 bacterial strain housing a BAC containing the full-length
IFNG gene. A 9.9 kb sequence containing the recombined locus was
retrieved from the BAC, cloned into pBR322, and introduced into a
C57BL/6-129 hybrid embryonic stem cell line and used to generate
chimeric mice. The neomycin cassette was removed by crossing
chimera offspring with beta-actin Cre-transgenic mice and
confirmed by Southern analysis. Subsequent genotyping was per-
formed by PCR with Primer 1 forward, 50-TTA GGT CAA CAA CCC
ACA GGT CCA-30; Primer 1 reverse, 50-AGT TGA GGA GAC AGA ACC
GCG GTG -30; Primer 2 forward, 50-GCC AAG CAT TCA ATG AGC-30;
Primer 2 reverse, 50-AAT ACT TCT TTG GTT GAT GC-30. PCR product
sizes are 284 nt and 224 nt for primer sets 1 and 2, respectively.
Two ARE-Del lines, derived from individual ES cell clones, were
selected and backcrossed at least 10 generations onto C57BL/6.
After backcrossing, mouse genetic backgrounds were assessed at
the DartMouse Speed Congenic Core Facility at the Geisel School
of Medicine at Dartmouth. DartMouse interrogated 1449 SNPs
spread throughout the genome using an Illumina, Inc. (San Diego,
CA) GoldenGate Genotyping Assay. The raw SNP data were
analyzed using DartMouse’s SNaP-Map and Map-Synth soft-
ware, allowing for genetic background at each SNP location to be
determined for individual mice from both ARE-Del breeding lines.
Animal care was provided in accordance with the procedures out-
lined in the “Guide for Care and Use of Laboratory Animals” (Na-
tional Research Council; 2011; National Academy Press:
Washington, D.C.)
2.2. Cell isolation for flow cytometry analysis
Bone marrow cells were recovered by flushing the femurs and
tibias with RPMI supplemented with 10% fetal calf serum, 2 mM L-
glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, 0.5 mM
EDTA (RPMI/EDTA). Leukocytes were isolated from spleen by me-
chanical disruption of tissue through a filtra-bag mesh (Fisher
Scientific) in 10 ml (RPMI/EDTA). Cells counts were determined
from the disrupted tissues using a Sysmex KX-21 (Roche) auto-
mated cell counter.
2.3. Flow cytometry analysis
Cells were stainedwith antibodies specific for B220, CD19, CD21,
CD23, IgM, CD11c, PDCA1, Siglec H, CD86, CD95, GL7, CD4, CD8, F4/
80, and Ly6G (eBioscience), CD43, CD80, I-A/I-E, IFN-g, and IgD
(Biolegend). IFN-g Intracellular labeling was done following cell
fixation with Cytofix/Cytoperm kit (PharMingen), according to
manufacturer’s suggested protocol. Data was acquired on a LSRII
flow cytometer (BD Biosciences). Data files were analyzed using FCS
Express software (De Novo).
2.4. Spleen marginal zone immunofluorescence staining
Tissue isolation and slide preparation were performed as pre-
viously described [18]. Tissue sections were stainedwith antibodies
specific for CD4 (L3T4; R&D Systems), CD169 (c3D6.112; AbDSer-
otec), MARCO (ED31; AbDSerotec), B220 (RA3-6B2; BD), and F4/80
(BM8; Ebioscience).
2.5. Cytokine, Flt3L, and complement C3 measurement and
antibody titers
Serum cytokines were analyzed using the mouse cytometric
bead array inflammation kit (BD Biosciences) on a FACScan flow
cytometer affixed with a 488-nm laser (Becton Dickinson Immu-
nocytometry Systems). IFN-a measurement was performed by
ELISA (PBL Interferon Source) at various times following R848
(Invivogen) addition to splenocytes. Complement C3 (Kamiya
Biomedical), IFN-g (Biolegend) and Flt3L (Novus Biologicals)
detection was performed using ELISA following manufacturer’s
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protocol. Mouse serum IgG, IgG1, IgG2b IgG2c, IgG3, IgA, and IgM
titers were measured using Ready-Set-Go ELISAs (Ebioscence). All
assays were performed according to manufacturer’s protocol.
2.6. Anti-DNA and ANA analysis
Serum ANA analysis was performed using a fluorescent HEP-2
ANA assay according to manufacturer’s protocol (Immuno-
concepts). Serum anti-DNA IgG measurements were performed by
coating microtiter plates with single and double-stranded DNAs.
Serumwas added to plates and bound antibodywas detected by the
addition of alkaline phosphatase (AP)econjugated goat anti-mouse
IgG (Southern Biotechnology) as previously described [19]. Anti-
DNA Ig reactivity was also measured using mouse anti-dsDNA
ELISAs specific for IgG, IgG1, and IgG3 with assays performed ac-
cording to manufacturer’s protocol (Alpha Diagnostic Interna-
tional). For IgG2c-specific anti-dsDNA activity, an anti-dsDNA ELISA
assay was modified by substituting an anti-mouse IgG2c-HRP
antibody (Alpha Diagnostic International) for the anti-mouse IgG-
HRP antibody supplied in the kit.
2.7. Renal immunopathology, blood urea nitrogen, and blood count
methods
One kidney from each mouse was frozen in OCT compound,
while the second fixed in 10% buffered neutral formalin and
paraffin-embedded. Both were sectioned at 5 microns. Paraffin
embedded sections were stained with periodic acid Schiff (PAS)
while frozen sections were stained with pan-immunoglobulin Goat
F(ab’)2 anti-Mouse IgM þ IgG þ IgA (H þ L) biotin conjugated
(Southern Biotechnology) and anti-complement component C3d (R
& D Systems), biotinylated by the investigator.
Plasma levels of blood urea nitrogen (BUN) assay was performed
by NCI-Frederick Pathology/Histotechnology Laboratory (Frederick,
MD). CBCs were performed on blood samples collected from the
periorbital sinus and analyzed using a Hemavet analyzer.
2.8. In vivo clodronate injections
To measure the effect of clodronate liposomes (CLL) adminis-
tration onmarginal zonemacrophages and potential autoimmunity
development, groups of 5 WT and 5 heterozygous ARE-Del (ARE-
Delþ/) mice were injected IV once weekly with 167 mg CLL or PBS
liposomes (Encapsula Nanosciences) in 200 ml suspension solution.
After 12 weeks, mice were euthanized and blood taken for serum
isolation and anti-DNA antibody analysis. Spleen tissue was
extracted and examined for loss of marginal zone macrophages by
immunoflorescent staining and confocal microscopy as described
above. Two animals per treatment group were examined. Kidneys
were removed, fixed in 10% buffered neutral formalin, paraffin-
embedded, and sectioned at 5 microns. Paraffin embedded sec-
tions were stained with periodic acid Schiff (PAS) and examined for
kidney lesions. Two animals per treatment group were examined.
2.9. In vitro pDC culture
Tibias and femurs ofWTand ARE-Del/micewere flushedwith
RPMI-1640 containing 10% FCS, 2 mM L-glutamine, 100 U/ml
penicillin, 100 mg/ml streptomycin, 50 mM b-mercaptoethanol, and
10 mM HEPES. Cells were washed, ACK treated for 5 min to lyse
RBCs, washed again and plated at a density of 1106 cells/ml. Flt3L
(Peprotech) þ/ IFN-g were added at final concentrations of
100 ng/ml and 10 U/ml, respectively, with additions on days 0 and
6. Cells were maintained in 37 C incubator with 5% CO2 and har-
vested at days 0, 3, 6, and 9 for FACs analysis and RNA isolation.
2.10. RNA Isolation, RNA half-life determination, and gene
expression analysis
Total RNA was isolated using RNeasy kit (Qiagen) and reverse
transcribed into cDNA using superscript III first-strand synthesis
system (Invitrogen). Quantitative real time PCR (qRT-PCR) was per-
formed on an Applied Biosystems 7300-real time PCRmachinewith
gene-specific Taqman probes (Invitrogen) for murine IRF-8, E2-2,
and HPRT. IFN-g mRNA expression in different tissues was deter-
mined using the nCounter Analysis System (NanoString Technol-
ogies) as previously described [20]. RNA half-life studies performed
on splenocytes from ARE Del/ and WT mice with cells placed in
culture for 3 h with PMA/ionomycin stimulation followed with
Actinomycin D at 2.5 mg/ml. RNAs isolated at various times and qRT-
PCR performed on cDNAs derived from cellular RNAs to determine
IFN-g and actin mRNA levels. IFN-g expression was normalized to
actin. Values were plotted to determine IFN-g mRNA half-life.
2.11. Statistics
Data sets were analyzed for statistical significance by two-tailed
MannWhitney U or Unpaired Students T test using Graphpad Prism
software. P-values less than 0.05 were considered significant.
3. Results
3.1. Generation of IFN-g ARE-Del mice
The 162 nt ARE sequence containing five AUUUA elements and
located in the 50 portion of the IFN-g 30UTR is highly conservedwith
83% identity between human and mouse (Supplemental Fig. 1A).
Sequence Replacement was accomplished using recombineering
technology (Supplemental Fig. 1B) and confirmed by Southern and
PCR analyses (Supplemental Fig. 1C and D). Two lines of ARE-Del
mice were generated from different C57BL/6-129 hybrid ES cell
clones and were backcrossed more than 10 times on to a C57BL/6
background. Initial characterization of backcrossed mice from both
lines revealed auto-reactivity. Because the mice were generated
from 129 ES cell hybrids, we were aware that C57BL/6 mice that
carry a 129 interval on chromosome 1 display an autoimmune
phenotype [21]. The genetic background for each ARE-Del line was
determined and found to contain only C57BL/6 sequence on chro-
mosome 1 (Supplemental Fig. 2 A and 2B). Both ARE-Del lines
contain a small amount of homozygous 129 sequence on chromo-
some 3. This region did not contribute to autoimmunity because
both ARE-Del/ and ARE-Delþ/þ contained the sequence but only
ARE-Del/ mice developed an autoimmune phenotype. The area
around the recombined IFNG gene in ARE-Del Line 1 was entirely
C57BL/6; however amixture of C57BL/6 and 129 DNAwas identified
in this region of ARE-Del Line 2. Again, only ARE-Del/ mice from
both lines developed a disease phenotype demonstrating that 129
DNA in the region didnot contribute to autoimmunity. BothARE-Del
lines were similar with regard to all physiological read outs sug-
gesting that changes in the 30UTR of the IFNG gene was responsible
for disease development. Mice homozygous for the ARE-Del
replacement are similar in appearance to WT littermate controls
but are not fertile. To obtain ARE-Del/ mice, ARE-Delþ/ mice are
inter-bred, yet, the percentage of ARE-Del/ mice at weaning is
significantly decreased compared to the expected Mendelian ratio,
with approximately 11% of pups homozygous for the deletion.
3.2. IFN-g mRNA levels are stabilized in IFN-g ARE-deleted mice
The promoter and protein coding regions of the IFNG gene in
ARE-Del mice are unaltered and produce an unmodified full-length
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IFN-g protein. However, deletion of five AUUUA sequences in the
30UTR suggested alterations in IFN-g mRNA stability. To test this,
splenocytes from ARE-Del/ mice were stimulated for 3 h with
PMA/ionomycin followed by actinomycin D treatment. Under these
conditions, IFN-gmRNA half-life inWTmicewas approximately 2 h
with no reduction in IFN-g mRNA levels from ARE-Del/ mice
(Fig. 1A) suggesting that ARE deletion significantly stabilizes the
IFN-g mRNA.
We next asked if ARE deletion impacted tissue-specific IFN-g
mRNA expression and found significant differences in 4 of 6
investigated tissues (Fig. 1B). To determine whether the elevated
IFN-g mRNA levels correlated with increased IFN-g protein
expression, we performed ELISAs using serum from ARE-Del and
WT mice. In WT mice, serum IFN-g levels were below 5 pg/ml
whereas ARE-Delþ/ and ARE-Del/ mice displayed an average of
6.3 pg/ml and 27.6 pg/ml, respectively (Fig. 1C). Intracellular
staining demonstrated that under basal conditions, IFN-g was
present and significantly elevated in NK, NKT, CD4þ and CD8þ T
cells from ARE-Del/ mice (Supplemental Fig. 3A). Moreover, ARE-
Del/ NK, CD4þ and CD8þ T cells displayed significant IFN-g in-
creases following in vivo IL-12 treatment. Ex vivo treatment with
PMA/ionomycin demonstrated that other cell types such as gran-
ulocytes and B cells were capable of producing IFN-g but there was
no significant difference between WT and ARE-Del/ mice
(Supplemental Fig. 3B). Overall, these results reveal that targeted
substitution of the 162 nt AU-rich fragment eliminates important
negative regulatorymRNA sequences and elevates IFN-gmRNA and
protein levels in a cell specific manner.
3.3. ARE-Del/ mice present a SLE-like phenotype
IFN-g involvement in the development lupus-like autoimmu-
nity has been demonstrated by using IFN-g transgenic mice [1], a
pristane-induced lupus model [22], and spontaneous lupus models
such as NZB X NZW F1 and MRL-Faslpr [23,24]. In SLE patients, sera
IFN-g levels are elevated [25,26] and T cells express significantly
higher IFN-g amounts relative to normal donors [4,27]. Initial
complete blood count (CBC) analysis from ARE-Del/ mice
revealed monocytosis and neutrophilia (Supplemental Table 1),
cellular subsets that increase in both murine-like lupus [28] and
human SLE [29].
Autoantibodies, such as anti-nuclear antibodies (ANAs), occur
prior to and during SLE progression and correlate with disease
activity, particularly in patients with lupus nephritis [30]. Consis-
tent with the lupus-like phenotype, 4 month-old ARE-Del/ mice
displayed strong ANA reactivity (Fig. 2A) and elevated serum
antibody titers against single and double-stranded DNAs (Fig. 2B).
Interestingly, 2 month-old mice also had significantly higher levels
of serum anti-dsDNA antibodies (Supplemental Fig. 4) indicating a
correlation between elevated IFN-g and autoreactivity in very
young animals.
IFN-g drives IgG class switching from IgG1 to IgG2a/c [31e33].
To determine if elevated IFN-g expression in ARE-Del/ mice
showed an increase in IgG2a/c levels, we assayed serum Igs and
found that total IgG levels were similar between ARE-Del/ and
WT control mice (Supplemental Fig. 5). However, ARE-Del/
mice displayed reduced levels of IgG1 and IgG3 and had elevated
IgG2c titers consistent with the role of IFN-g in Ig class switching.
We also examined IgA and IgM serum levels and found no dif-
ference in IgA levels between groups. In contrast, IgM levels were
significantly elevated in the ARE-Del/ mice. To determine what
IgG isotype(s) contributed to the anti-dsDNA reactivity in the
ARE-Del mice, we determined serum IgG, IgG1, IgG2c and IgG3
anti-dsDNA titers and found that IgG2c was the major contributor
to the DNA autoreactivity (Fig. 2C). In other murine models of
lupus, IgG2a/c is reported to be a more pathogenic Ig isotype by
efficiently activating FcgammaRIII and FcgammaRIV receptors and
complement [34]. Thus, it is conceivable that IFN-g aids in lupus-
like disease development by its role immunoglobulin class
switching.
A serious manifestation of SLE is glomerulonephritis. We per-
formed histological analysis on renal sections from 4month oldWT
and ARE-Del/ mice. Periodic Acid Schiff staining revealed altered
glomerular structures, thickened mesangium and an absence of
Fig. 1. IFN-gmRNA stabilization in ARE-Del/ mice. (A) Splenocytes isolated from ARE
Del/ and WT littermate mice were placed in culture and stimulated with PMA plus
ionomycin for 3 h. Actinomycin D was added to cells and RNAwas isolated at the times
indicated. qPCR was performed to determine IFN-g and actin mRNA levels. IFN-g
expression was normalized to actin and values plotted to calculate IFN-g mRNA half-
life. Data was pooled from 12 individual ARE-Del/ and 12 WT mice. Data shown is
from one of two similar experiments. (B) RNA from 4-month old ARE-Del/ and WT
littermate mice was isolated from bone marrow, kidney, liver, lymph nodes, spleen,
and thymus. RNA was hybridized to a nanostring IFN-g specific nCounter reporter
probe and analyzed using the nCounter analysis system. Data generated were from 12
individual mice in ARE-Del/ and WT groups and expressed as mean  s.e.m. (C)
Serum samples obtained from 4-month old ARE-Del/, ARE-Delþ/, and WT mice
were analyzed for IFN-g by ELISA. Data plotted are mean  s.e.m. from 8 individual
mice per group. Statistical analysis was performed on data sets using ManneWhitney
U test, **P < 0.01.
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Fig. 2. ARE-Del/ mice display reactivity against nuclear antigens. (A) Serum obtained from ARE-Del/ and WT littermate mice was analyzed for ANA by indirect immunoflu-
orescence measurement using Hep2 cells. Data shown are from 3 individual ARE-Del/ and WTmice. (B) Anti-ssDNA and dsDNA serum IgG levels determined by ELISAs performed
on serum from four month old ARE-Del/ and WT mice. (C) Serum IgG, IgG1, IgG2c and IgG3-specific anti-dsDNA titers were determined by ELISA. Data in B and C represent
mean  s.e.m. for titers obtained from 11 to 12 mice per group. Statistical analysis was performed on data sets using ManneWhitney U test, ***P < 0.001.
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well-defined capillaries demonstrating moderate bilateral mesan-
gioproliferative glomerulonephropathy in the ARE-Del/ mice
(Fig. 3A). Pan-IgG/IgM and C3 complement staining showed
increased immunoglobulin and complement deposits throughout
the glomerular mesangium (Fig. 3B and C). SLE-associated
glomerular disease is often correlated with hypocomplementemia
and in ARE-Del/ mice we observed a significant reduction in
serum C3 complement levels (Fig. 3D). Blood urea nitrogen (BUN)
levels were slight but significantly elevated in the ARE-Del/ mice
(28.02  3.4 mg/dL, ARE-Del/ vs. 19.2  0.53 mg/dL WT)
demonstrating renal stress in these animals (Fig. 3E). Collectively,
these data strongly demonstrate that IFN-g ARE deletion pre-
disposes animals to a lupus-like syndrome with moderate renal
lesions by 4 months of age.
3.4. Chronic IFN-g levels impact cell populations involved in
autoimmunity
B cells and plasmacytoid dendritic cells (pDCs) are central for
SLE. B cells contribute to SLE pathogenesis through both antibody-
Fig. 3. ARE-Del/ mice display mesangioproliferative glomerulonephritis (A) Formalin fixed, paraffin-embedded kidney sections were stained with Periodic Acid Schiff (PAS). Short
arrows indicate normal glomeruli capillaries structure in WT mice. Glomeruli in ARE-Del/ mice display thickened basement membranes and increased cellularity (long arrows).
Original magnification  40. (B) Kidneys were embedded in OCT media, frozen, sectioned and stained with a Goat F(ab’)2 Anti-Mouse IgM þ IgG þ IgA (H þ L). Original
magnification  40. (C) Staining for complement C3 deposition in glomeruli from frozen kidney sections. Original magnification  100. (D) Serum Complement C3 levels were
determined by ELISA. Data plotted represent mean  s.e.m. from 5 individual mice per group. Statistical analysis performed on data sets using ManneWhitney U test, **P < 0.01. (E)
Blood urea nitrogen levels measured from plasma collected from WT and ARE-Del mice. Data represent mean  s.e.m. from 7 individual mice per group. Statistical analysis
performed on data sets using unpaired Students T test, *P < 0.05. Histology, C3, and BUN levels were all performed on 4 month-old mice.
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dependent and -independent mechanisms. pDCs express toll-like
receptors (TLRs), engage nucleic acid immune complexes, and
activate signaling pathways to facilitate production and release of
interferon alpha (IFN-a) a factor implicated in many of the detri-
mental effects in SLE.
ARE-Del/ mice have a significant increase in the percentage
and absolute number of pDCs cells in bone marrow and spleen
relative to WT mice (Fig. 4A and Supplemental Fig. 6A). This cor-
relates with increased serum Flt3L concentration in ARE-Del/
mice (Supplemental Fig. 6B) and increased IFN-a production
following TLR7 agonist addition to ARE-Del/ cultured splenocytes
(Supplemental Fig. 6C). To determine if IFN-g plays a role in pDC
development, bone marrow cells from ARE-Del/ and WT mice
were cultured in the presence of Flt3L and IFN-g and after 9 days,
Fig. 4. Enhanced pDC accumulation correlates with the increased IFN-g levels. (A) Single cell suspensions from bone marrow and spleens of WT and ARE-Del/ mice were stained
with antibodies against CD11c, PDCA1, MHC class II, and Siglec H. Data plotted represent mean  s.e.m. from 4 individual mice per group. Experiment performed 3 times with
similar results. (B) Single cell suspensions isolated from WT and ARE-Del/ bone marrow were placed into culture with Flt3L with and without IFN-g. After 9 days, the percent of
pDCs were evaluated by examining cell surface expression of CD11c, B220, Siglec H and PDCA1. Cell populations double positive for CD11c and B220 were gated on (left column)
then evaluated for Siglec H and PDCA1 expression (right column). (C) Graph of the relative percentages of CD11þ, B220þ pDCs as shown in B. (D) Quantitative real time PCR for IRF8
expression on cDNAs generated from RNA isolated fromWT and ARE-Del/ bone marrow cultured with Flt3L in the presence or absence of IFN-g. Top and bottom graphs represent
IRF8 expression in pDC cultures derived from WT and ARE-Del/ bone marrows, respectively. Data in both C and D are representative of 4 individual experiments. Statistical
analysis performed on data sets using unpaired Students T test, *P < 0.05; ***P < 0.001.
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IFN-g increased the percentage of pDCs in both the ARE-Del/ and
WT populations by approximately 2-fold (Fig. 4B and C). Surpris-
ingly, in the absence of exogenously added IFN-g, WT and ARE-
Del/ bone marrow cultures produced similar, lower percentages
of pDCs suggesting that constant IFN-g exposure is required to
enhance pDC development (Fig. 4B and C).
pDC Lineage commitment is dependent on E2-2 and IRF8
transcription factors [35]. IRF8 is best known as an IFN-g inducible
factor [36] involved in lineage development of hematopoietic cells
types including macrophages and B cells [37,38]. To ask if IFN-g
affects E2-2 and IRF8 expression, we examined the relative mRNA
expression of these factors at different days following Flt3L and
IFN-g addition to bonemarrow cultures. At day 0, IRF8 mRNA levels
were low in WT and ARE-Del/ cultures; however, basal IRF8
mRNA levels were slightly elevated in ARE-Del/ cells (Fig. 4D). By
day 9, both WT and ARE-Del/ cultures treated with IFN-g dis-
played a 30e40-fold increase in IRF8 mRNA whereas cultures
without IFN-g had only an approximately 20-fold increase. Since
E2-2 can directly augment IRF8 expression, we asked if IFN-g could
differentially enhance E2-2mRNA levels and found that E2-2mRNA
levels were similar in WT bone culture irrespective of IFN-g addi-
tion (Supplemental Fig. 6D). In contrast, the IFN-g-treated ARE-
Del/ bone marrow culture expressed 50% less E2-2 mRNA by day
9 (Supplemental Fig. 6D) suggesting that IFN-g enhances pDC
development in an IRF8 dependent manner that does not require
E2-2. Further work is needed to identify other transcription factors
involved in pDC development in response to IFN-g.
To determine if the increase in pDCs was specific or represented
a general change in dendritic cell populations in the ARE-Del/
mice, we examined the level of conventional dendritic cells (cDCs)
in spleen. The percent of spleen CD11chigh, MHC class IIhigh cDCs
was not significantly different between ARE-Del/ and WT mice
(Fig. 5A and C). When the cDC population was further segregated
into CD4þCD8e cDCs (CD4þ cDCs), double negative CD4eCD8e cDCs
(DN cDCs), and CD4eCD8þ cDCs (CD8þ cDCs) there was no differ-
ence in the CD8þ cDC populations between theWTand ARE-Del/
mice (Fig. 5B and D). Yet, an inverse relationship with regard to
CD4þ cDCs and DN cDCs between theWTand ARE-Del/ mice was
Fig. 5. IFN-g expression does not impact total cDC population in spleen. (A) Single cell suspensions from ARE-Del/ andWTmouse spleens were stained with CD11c and MHC class
II antibodies. (B) The CD11chigh MHC class IIhigh cDC population was gated and further examined for antibody staining against CD4, CD8 surface markers. (C) Graphical representation
of the total percent of cDCs in 9 individual WT and ARE-Del/ mice. (D) Graphical representation of CD4þ, CD8þ and CD4CD8 double negative cDC subpopulations in 9 individual
WT and ARE-Del/ mice. Data displayed in C and D indicate mean  s.e.m. for each data set. Statistical analysis performed on data sets using unpaired Students test, ***P < 0.001;
ns, not significant.
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observed (Fig.. 5B and D). WT mice had approximately equal per-
centages of both DN cDCs and CD4þ cDCs (38%) whereas ARE-Del/
 mice had 61% DN cDCs and 23% CD4þ cDCs. These data suggest
that the overall cDC population is not affected by IFN-g expression
and further supports a cell-specific role for IFN-g in pDC develop-
ment. However, it is interesting that some cDC subpopulations are
altered. How this effects the biology of the ARE-Del/ animals has
not been determined.
Examination of bone marrow B cells indicated no significant
differences between ARE-Del/ andWTmice (Fig. 6A). Yet, in ARE-
Del/ spleen, there was an approximate 20 percent reduction in
the total B220þ, CD19þ cell population (Fig. 6B) with a concurrent
increase in B220þ, CD19þ cells in lymph nodes (Supplemental
Fig. 7) that was possibly due to increased B cell trafficking to this
tissue. In spite of the total B cell decrease the percent of CD95þ,
GL7þ germinal center (GC) B cells increased (Fig. 6C), an observa-
tion consistent with increased autoantibody production and lupus-
like disease. The ARE-Del/ B cell population expressed CD80 and
CD86 activation markers (Fig. 6C) and closer examination of this
population indicated no change in CD23hi, CD21lo follicular B cell
subset. However, the percentage of CD23null, CD21hi marginal zone
B (MZB) cells was greatly reduced or absent (Fig. 6C).
3.5. ARE-Del mice lose MZMs and develop autoimmunity
The spleen marginal zone represents the boundary between the
lymphoid white pulp and erythrocyte-rich red pulp and is resident
to both MZB cells and marginal zone macrophages (MZMs). As
Fig. 6. Loss of marginal zone B cells in splenic ARE-Del/ CD19þ B220þ B cell population. (A) Bone marrow cells from ARE-Del/ and WT mice were stained with B220 and CD19
antibodies. Percentage of cells expressing these markers is shown. (B) Percent B220þ CD19þ cells in spleens of ARE-Del/ and WT mice were determined. (C) B220þ CD19þ CD43
splenocytes were gated and examined for CD95, GL7, CD80, CD86, CD23 and CD21 expression IgD, IgM expression also examined but not shown. Plots are representative of data
generated in 3 independent analyses with 3e4 mice per group. (D) Graphs represent cumulative data from experiments used to generate FACs plots in C with mean  s.e.m.
provided for each data set. Statistical analysis performed on data sets using ManneWhitney U test, ***P < 0.001; ns, not significant.
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these cells are functionally and developmentally interdependent
[39,40], severe reductions in MZB cells could place spleen MZM
development and residence in jeopardy. Confocal microscopy of
ARE-Del/ mouse spleen showed a reorganization of the splenic
cellular compartments with ill-defined B and T cells zones, F4/80
red pulp macrophages present, but an absence of CD169þ, MARCOþ
MZMs (Fig. 7). MZMs have been shown to play a role in removal of
endogenous apoptotic cells to prevent autoimmune responses [41].
This is consistent with heterozygous ARE-deletion (ARE-Delþ/)
mice that partially retain their MZBs and MZMs (Fig. 8A) and have
either no or very weak autoimmune effects as demonstrated by
only a slight but non-significant elevation in anti-DNA antibody
levels (Fig. 8B). Because of this, we asked if selective MZMs removal
would induce these animals to become more sensitive to “self” and
develop autoimmune symptoms similar to the ARE-Del/ mice.
WT and ARE-Delþ/ mice were injected once weekly with 167 mg
clodronate, a dosage that eliminates MZMs but allows red pulp
macrophages to remain [41]. After 12 weeks, mice were examined
for loss of MZMs, serum anti-DNA antibodies, and kidney lesions.
Confocal imaging demonstrated that the low dose clodronate
selectively removed the MZMs (Fig. 8A) and was concomitant with
a significant increase in anti-DNA antibody levels in the clodronate
treated ARE-Delþ/ mice as compared to clodronate-treated WT
and liposome-injected control ARE-Delþ/ mice (Fig. 8C). Kidney
lesions were evident in both the control and clodronate-treated
ARE-Delþ/ and was likely due to chronic exposure to circulating
IFN-g. However, clodronate-treated ARE-Delþ/ mice displayed
increased immunoglobulin deposits, lymphocytic infiltrates and a
more severe mesangioproliferative glomerulopathy (Fig. 8D,
Supplemental Fig. 8, Supplemental Table 2) suggesting an increase
in autoimmune-related tissue destruction.
4. Discussion
Our current work has focused on consequences of disrupted
IFN-g posttranscriptional control through deletion of a multi-ARE
RNA regulatory region in the IFN-g 30UTR. AREs are associated
with RNA destabilization and we predicted that removal of five
AREs in the IFN-g 30UTR would stabilize the IFN-g mRNA. Indeed
we observed a dramatic increase in IFN-g mRNA half-life that
translated into chronic low levels of circulating IFN-g in mice.
The syndrome in ARE-Del/ mice develops by 16 weeks of age
and is similar to human SLE in that it manifests itself by autoanti-
body production and renal glomerulopathy. Autoantibody pro-
duction in 8-week old ARE-Del/ mice shows similarity to human
SLE in that autoantibodies are often detected well in advance of
clinical disease onset [30]. Moreover, elevated autoantibodies
correlate with neutrophilia in both the ARE-Del/ model and in
human SLE which, in turn, plays a role in vascular breakdown, and
lupus nephritis [29].
pDCs are uniquely suited to promote SLE development because
of restricted TLR-7 and -9 expression patterns [42] and the capacity
to produce elevated IFN-a levels [43]. Our finding that ARE-Del/
bone marrow had increased pDC numbers was unexpected. The
molecular basis for bone marrow pDC lineage commitment is
dependent upon multiple transcription factors and their relative
expression levels. IRF-8 is an important transcription factor in pDC
development as demonstrated by pDC loss in IRF8 deficient mice
and in vitro Flt-3L treated bone marrow cultures from IRF-8 defi-
cient mice [44,45]. Our study found that IRF8mRNA expressionwas
significantly increased in bone marrow pDC cultures treated with
IFN-g. Moreover, cells from both WT and ARE-Del/ bone marrow
responded similarity to IFN-g stimulation suggesting that IFN-g
Fig. 7. Loss of marginal zone B cells is coincident with loss of marginal zone macrophages in ARE-Del/ mice. Confocal immunofluorescent images of spleen sections from ARE-
Del/ andWTmice. Anti-B220, anti-CD4, and anti-F4/80 were used to detect B lymphocytes, T lymphocytes, and red pulp macrophages, respectively. Anti-CD169 and MARCO were
used for marginal zone macrophage detection. White bars on images represent 300 mm.
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pre-exposure in ARE-Del/ mice was not a prerequisite for
response or magnitude of response to IFN-g. E2-2 is central to pDC
development as illustrated by the absence of pDCs from E2-2
deficient hematopoietic progenitors [35]. Interestingly, E2-2 has
been shown to bind to Irf8 promoter [35] suggesting that IRF8
expression is downstream of E2-2. Our study found that E2-2
expression is present but not altered in ARE-Del/ mice. Thus,
IFN-gmay eliminate the need for enhanced E2-2 levels and instead,
via-IRF8, aid E2-2 to push pDC gene expression.
The marginal zone is a highly specialized structure that allows
innate and adaptive immune cells to interact in response to path-
ogens. Resident MZB cells are positioned in close proximity to
Fig. 8. Low dose clodronate treatment eliminates marginal zone macrophages and enhances autoimmune reactivity. (A) Confocal immunofluorescent images of spleen sections
from ARE-Delþ/ andWTmice treated with control liposomes or clodronate for 12 weeks. Anti-B220, anti-CD4, and anti-F4/80 used to detect B lymphocytes, T lymphocytes, and red
pulp macrophages, respectively. Anti-CD169 was used to detect marginal zone macrophages. Images represent one of two animals examined per treatment group. (B) Anti-dsDNA
IgG measurements were performed on serum from untreated WT and ARE-Delþ/ mice to determine a baseline for autoantibody reactivity. Graph includes mean  s.e.m. for 6 mice
per group. (C) Anti-dsDNA IgG reactivity of serum from WT and ARE-Delþ/ mice following 12 weeks of treatment with control liposomes or clodronate. Anti-dsDNA IgG results
shown in 8C represent one of two experiments, each with 5 animals per treatment group. (D) PAS staining of formalin-fixed kidney sections from WT and ARE-Delþ/ treated with
control liposomes or clodronate. Original magnification  100. Image from one of two animals examined is shown. Statistical analysis was performed on data sets 8B and 8C using
unpaired Students T test, ***P < 0.001; ****P < 0.0001; ns, not significant. White bars on confocal images represent 300 mm. CLL, clodronate lipsomes.
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specialized MZMs that express both MARCO and CD169 receptors
and act as phagocytic cells for clearance of blood-borne pathogens
and apoptotic materials. Additionally, MZB cells are required for
normal marginal zone development as well as the presence and
function of MZMs [40]. The lack of MZB cells in ARE-Del/ mice
lead us to ask if the MZM population was altered and indeed we
observed a complete MZM absence in homozygote but not het-
erozygote mice. As recently shown, elimination of MZMs promotes
autoimmunity onset in WT mice injected with apoptotic cells [41].
This led us to ask whether ARE-Delþ/ mice, that retain MZB and
MZMs and are resistant to autoimmunity, could be pushed to an
autoimmune state. We performed a low-dose clodronate injection
regiment and found autoantibody development as well as
glomerulonephritis in ARE-Delþ/ mice. In contrast to WT mice,
ARE-Delþ/ mice did not require injection of apoptotic cells. This
suggested that chronic low IFN-g levels may be effective for
apoptosis incidence; however, the mechanism and susceptible cell
types is currently not known. IFN-g induces apoptosis in a variety of
cells so it is not without precedence that low chronic levels of IFN-g
could promote autoimmunity through increased inflammatory
states, cellular disruption and imbalanced homeostasis in immune
tissues.
The conserved ARE controls IFN-g expression by altering IFN-g
mRNA half-life; yet the molecular mechanism responsible for this
is not entirely understood. Work by Ogilvie et al. provided evi-
dence for tristetraprolin (TTP) control of IFN-g expression through
TTP binding to an 18 nucleotide region in the conserved IFN-g
ARE region. Additionally, they showed that IFN-g mRNA and
protein were elevated in TTP knockout mice [14]. Our laboratory
has identified a miRNA binding site 30 to the IFN-g ARE-sequence
that, by SHAPE analysis [46], is spatially close to the TTP binding
region. Interestingly, miRNA binding to this sequence stabilizes
IFN-g mRNA. The proximity of the TTP and miRNA binding sites
make it plausible that proteins associated with miRNA binding
may occlude TTP binding and block subsequent destabilization of
IFN-g mRNA (Savan, R. et al. manuscript submitted). Another
possibility is that certain cytokines may trigger events leading to
the inactivation of TTP interactions with IFN-g mRNA. Previous
work by our laboratory has shown that IL-12 mediates perinuclear
accumulation of IFN-g mRNA [11]. IL-12 partially controls IFN-g
expression through p38 MAPK that in turn, activates the down-
stream kinase MK2. MK2 is an important mediator of post-
transcriptional control by direct phosphorylation and inactivation
of TTP, resulting in mRNA stabilization [47]. Thus, it is intriguing
to hypothesize that IL-12 may alter IFN-g mRNA stability and
localization by the actions of MK2 on TTP. This may result in
enhanced miRNA/IFN-g mRNA binding that ultimately associates
the complex with the nuclear membrane. Ribonuclear protein(s)
involved in such a mechanism are unknown and a better under-
stating of how ARE elements, miRNAs and RNA-binding proteins
coordinate IFN-g expression is currently under investigation in
our laboratory.
5. Conclusions
Our findings demonstrate that small alterations in the IFN-g
signaling pathway lead to detrimental systemic outcomes in host
immune physiology and response that is dependent upon crossing
a “threshold” level of circulating IFN-g. Thus, the need for multi-
faceted control of IFN-g expression is imperative for proper im-
mune function and well-being. The ARE-Del/ mouse highlights
this point demonstrating a connection between uncontrolled low
IFN-g levels and autoimmunity and suggest that a therapeutic
blockade of the IFN-g signaling pathway may provide an effective
treatment for autoimmunity and in particular SLE.
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